Cerulean Pharma Inc., a privately held developer of cancer drugs delivered by tiny nanoparticles, has launched a Phase 2 study of its lead drug candidate in ovarian cancer patients who are resistant to some other drugs.
The ovarian cancer study is targeting patients whose cancer has advanced despite treatment with standard platinum therapy. The trial is being conducted at Massachusetts General Hospital in cooperation with the Dana-Farber Cancer Institute, Brigham and Women?s Hospital, and Beth Israel Deaconess Medical Center.
?This trial is intended to build on our current clinical data and determine if CRLX101 can offer ovarian cancer patients a new treatment option,? said Edward Garmey, M.D., chief medical officer of Cerulean, in a statement. ?We are excited to partner with Dr. Krasner [MGH principal investigator Dr. Carolyn Krasner] and to expand the development strategy of CRLX101 in an indication with such high unmet needs.?
The Cambridge, Mass. company?s drug candidate, known as CRLX101, has already been evaluated in a Phase 2 study against advanced non-small-cell lung cancer. Cerulean also plans to launch trials evaluating the potential therapy, which delivers medicine directly to the tumor, in other types of cancer.
Health Care/Life Sciences
Follow your favorites with My News
My News is a way to create a customized news feed based on companies and industries that matter to you.
Source: http://feeds.bizjournals.com/~r/bizj_national/~3/dsPAz5ID83E/cerulean-pharma-launches-ovarian.html
fat tuesday obama sweet home chicago accenture match play george washington carver king cake mardi gras fun.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.